Estimating the influence of physicians on the underuse of drugs in diabetic nephropathy in Taiwan

Journal of Nephrology

Volumn 26, Issue 1, 2013, Pages 16-24

  Huang, Li Ying ^a,b   Yeh, Hseng Long ^c,d   Su, Syi ^b   Wang, Ting Chung ^c   Hsieh, Jun Yi ^e  

^a Center for Drug Evaluation   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e UNIVERSITY OF TAIPEI   (Taiwan)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Diabetic nephropathy; Hierarchic linear model

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOCTOR PATIENT RELATION; DRUG EFFECT; DRUG USE; FEMALE; GENDER; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; TAIWAN; WORK EXPERIENCE;

EID: 84877094500     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000170     Document Type: Article

References (30)

1. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999;341(15):1127-1133.
2. Bureau of National Health Insurance. National Health Insurance Annual Statistical Report, 2000. Available at: http:// www.doh.gov.tw/CHT2006/DM/DM2_p01.aspx?class_ no=117&now_fod_list_no=4146&level_no=1&doc_no=38031. Accessed June 30, 2010.
3. Fioretto P, Mauer M. Reversal of diabetic nephropathy: lessons from pancreas transplantation. J Nephrol. 2012;25(1): 13-18.
4. Gupta A, Gupta P, Biyani M. Targeted therapies in diabetic nephropathy: an update. J Nephrol. 2011;24(6):686-695.
5. Bureau of National Health Insurance. About the Program. Available at: http://www.nhi.gov.tw/english/index.asp?menu= &menu_id=30. Accessed June 17, 2010.
6. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006;(4): CD006257.
7. Frische S. Glomerular filtration rate in early diabetes: ongoing discussions of causes and mechanisms. J Nephrol. 2011; 24(5):537-540.
8. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355(9200): 253-259.
9. Molitch ME, DeFronzo RA, Franz MJ, et al; American Diabetes Association. Nephropathy in diabetes. Diabetes Care. 2004;27 Suppl 1:S79-S83.
10. Bennett PH, Haffner S, Kasiske BL, et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis. 1995;25(1):107-112.
11. Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis. 2005;46(6):1080-1087.
12. Yeh HL, Huang LY, Su S, Yang MC, Wang TC. Underuse of ACE inhibitors and angiotensin II receptor blockers among patients with diabetic nephropathy in Taiwan. Health Policy. 2011;100(2-3):196-202.
13. Bingenheimer JB, Raudenbush SW. Statistical and substantive inferences in public health: issues in the application of multilevel models. Annu Rev Public Health. 2004;25(1): 53-77.
14. Diez-Roux AV. Multilevel analysis in public health research. Annu Rev Public Health. 2000;21(1):171-192.
15. Schmieder RE, Ruilope LM, Barnett AH. Renal protection with angiotensin receptor blockers: where do we stand. J Nephrol. 2011;24(5):569-580.
16. Chiang TL. Taiwan's 1995 health care reform. Health Policy. 1997;39(3):225-239.
17. Huang P, Hsu YH, Kai-Yuan T, Hsueh YS. Can European external peer review techniques be introduced and adopted into Taiwan's hospital accreditation system? Int J Qual Health Care. 2000;12(3):251-254.
18. Bureau of National Health Insurance. National Health Insurance Research Database. Available at: http://w3.nhri.org.tw/ nhird//date_01.html. Accessed October 22, 2010.
19. Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis. 2005;46(2):225-232.
20. Moineddin R, Matheson FI, Glazier RH. A simulation study of sample size for multilevel logistic regression models. BMC Med Res Methodol. 2007;7(1):34.
21. Snijders T, Bosker R. Modeled variance in two-level models. Sociol Methods Res. 1994;22(3):342-363.
22. Siddiqui O, Hedeker D, Flay BR, Hu FB. Intraclass correlation estimates in a school-based smoking prevention study. Outcome and mediating variables, by sex and ethnicity. Am J Epidemiol. 1996;144(4):425-433.
23. Neves S, Santos R, Gomes C, Correia AJ. [Fetopathy associated with exposure to angiotensin converting enzyme inhibitors]. Acta Med Port. 2010;23(4):697-700.
24. Martin U, Foreman MA, Travis JC, Casson D, Coleman JJ. Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. J Clin Pharm Ther. 2008;33(5):507-511.
25. Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev. 2006;82(1):23-28.
26. Chiang CE, Wang TD, Li YH, et al; Hypertension Committee of the Taiwan Society of Cardiology. 2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc. 2010;109(10):740-773.
27. Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens. 2000;18(11):1671-1675.
28. Schmieder RE, Bakris G, Weir MR. Telmisartan in incipient and overt diabetic renal disease. J Nephrol. 2011;24(3): 236-273.
29. Degli Esposti L, Saragoni S, Buda S, et al. Awareness of albuminuria in an Italian population-based cohort of patients treated with hypoglycemic drugs. J Nephrol. 2011;0. Epub ahead of print.
30. Forsetlund L, Bjørndal A, Rashidian A, et al. Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2009;(2):CD003030.